{"filing":{"accession_number":"0001628280-26-049103","cik":"0000010795","ticker":"BDX","company_name":"BECTON DICKINSON \u0026 CO","form":"8-K","filing_date":"2026-07-22","report_date":null,"primary_document":"bdx-20260719.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/10795/000162828026049103/bdx-20260719.htm"},"events":[{"id":19312,"run_id":17374,"accession_number":"0001628280-26-049103","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Michael D. Garrison, Executive Vice President and President of the Medical Essentials and BioPharma Systems segments, informed BD of his intention to retire effective October 2, 2026, after more than 20 years with the company. The filing also discloses an organizational restructuring whereby BioPharma Systems will report directly to the CEO following his departure.","company_name":"BECTON DICKINSON \u0026 CO","ticker":"BDX","filing_date":"2026-07-22","form":"8-K","submitted_at":null,"items":[{"id":18368,"accession_number":"0001628280-26-049103","item_number":"5.02","item_title":"DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Michael D. Garrison, Executive Vice President and President of the Medical Essentials and BioPharma Systems segments, informed BD of his intention to retire effective October 2, 2026, after more than 20 years with the company. The filing centers on his departure and the organizational restructuring that follows (BioPharma Systems reporting directly to the CEO), making this a material executive departure that would affect investor assessment of leadership continuity and operational structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T10:59:38.940374+00:00","company_name":"","ticker":null,"filing_date":""},{"id":18369,"accession_number":"0001628280-26-049103","item_number":"7.01","item_title":"REGULATION FD DISCLOSURE","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Dr. Michael Garrison, executive vice president and president of the Medical Essentials and BioPharma Systems segments, is retiring effective October 2, 2026, after more than 20 years with BD. The press release emphasizes his significant impact and leadership roles across multiple business segments. This is a material departure of a senior executive responsible for two major business segments at a large medical technology company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T10:59:38.940374+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":18368,"accession_number":"0001628280-26-049103","item_number":"5.02","item_title":"DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Michael D. Garrison, Executive Vice President and President of the Medical Essentials and BioPharma Systems segments, informed BD of his intention to retire effective October 2, 2026, after more than 20 years with the company. The filing centers on his departure and the organizational restructuring that follows (BioPharma Systems reporting directly to the CEO), making this a material executive departure that would affect investor assessment of leadership continuity and operational structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T10:59:38.940374+00:00","company_name":"BECTON DICKINSON \u0026 CO","ticker":"BDX","filing_date":"2026-07-22"},{"id":18369,"accession_number":"0001628280-26-049103","item_number":"7.01","item_title":"REGULATION FD DISCLOSURE","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Dr. Michael Garrison, executive vice president and president of the Medical Essentials and BioPharma Systems segments, is retiring effective October 2, 2026, after more than 20 years with BD. The press release emphasizes his significant impact and leadership roles across multiple business segments. This is a material departure of a senior executive responsible for two major business segments at a large medical technology company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T10:59:38.940374+00:00","company_name":"BECTON DICKINSON \u0026 CO","ticker":"BDX","filing_date":"2026-07-22"}]}